Skip to main content

Advertisement

Log in

Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The aim of this study was to assess the early effects of zoledronic acid (ZOL) and oral ibandronate (IBA) on the bone resorption marker s-CTX (serum C-telopeptide of collagen type I) and the bone formation marker B-ALP (bone-alkaline phosphatase) in patients with bone metastases from non-small cell lung cancer (NSCLC).

Methods

Fifty-five patients with at least one site of bone metastasis secondary to NSCLC were randomly assigned to receive intravenous ZOL 4 mg every 4 weeks, or oral IBA 50 mg/day.

Results

At 1 month of treatment, s-CTX was reduced by 54.8% (95% CI 40.4–59.8%) in the ZOL group (26 evaluable patients) compared with 38.2% (95% CI 29.8–48.7%) in the oral IBA group (27 evaluable patients) (p = 0.03). At 3 months, s-CTX was reduced by 72.6% (95% CI 58.6–71.3%) in the ZOL group, compared with 66.4% (95% CI 54.3–79.5%) in the oral IBA group (p = 0.22). Both bisphosphonates similarly decreased the bone marker B-ALP at 1 month (ZOL 24.7%, 95% CI 3.6–39.5%, and IBA 24.2%, 95% CI 2.8–43.4%) and 3 months (ZOL 28.6%, 95% CI +2.8–43.3%, and IBA 24.2%, 95% CI 3.2–47.4%). Both bisphosphonates were well tolerated.

Conclusion

Considering the changes in bone markers, ZOL and oral IBA show comparable efficacy in patients with NSCLC and bone metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Clezardin P, Teti A (2007) Bone metastasis. Clin Exp Metastasis 24:599–608

    Article  PubMed  CAS  Google Scholar 

  2. Coleman RE, Purohit OP, Vinholes JJ et al (1997) High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 80(Suppl 8):1686–1690

    Article  PubMed  CAS  Google Scholar 

  3. Lipton A (2003) Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 8:469–488

    Article  PubMed  CAS  Google Scholar 

  4. Cameron D, Fallon M, Diel I (2006) Ibandronate: its role in metastatic breast cancer. Oncologist 11(Suppl 1):27–33

    Article  PubMed  CAS  Google Scholar 

  5. Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558–567

    PubMed  CAS  Google Scholar 

  6. Berenson JR, Rosen LS, Howell A et al (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191–1200

    Article  PubMed  CAS  Google Scholar 

  7. Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostate Dis 5:231–235

    Article  CAS  Google Scholar 

  8. Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405

    Article  PubMed  Google Scholar 

  9. Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133–1137

    Article  PubMed  CAS  Google Scholar 

  10. Francini G, Gonnelli S, Petrioli R et al (1992) Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 10:591–598

    PubMed  CAS  Google Scholar 

  11. Coleman RE (2002) The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94:2521–2533

    Article  PubMed  Google Scholar 

  12. Brown JE, Thomson CS, Ellis SP et al (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031–2037

    Article  PubMed  CAS  Google Scholar 

  13. Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925–4935

    Article  PubMed  CAS  Google Scholar 

  14. Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69

    Article  PubMed  CAS  Google Scholar 

  15. Hannon RA, Eastell R (2006) Bone markers and current laboratory assays. Cancer Treat Rev 32(Suppl 1):7–14

    Article  PubMed  CAS  Google Scholar 

  16. Hamaoka T, Madewell JE, Podoloff DA et al (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942–2953

    Article  PubMed  Google Scholar 

  17. Melzack R (1975) The McGill Pain Questionnaire: major properties and scoring methods. Pain 1:277–299

    Article  PubMed  CAS  Google Scholar 

  18. De Benedittis G, Massei R, Nobili R et al (1988) The Italian Pain Questionnaire. Pain 33:53–62

    Article  PubMed  Google Scholar 

  19. McCormack A, Hunter-Smith D, Piotrowski ZH et al (1992) Analgesic use in home hospice cancer patients. J Fam Pract 34:160–164

    PubMed  CAS  Google Scholar 

  20. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:216

    Article  Google Scholar 

  21. Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69:1375–1381

    PubMed  CAS  Google Scholar 

  22. Lipton A (2008) Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34(Suppl 1):S25–S30

    Article  PubMed  CAS  Google Scholar 

  23. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol 19:420–432

    Article  PubMed  CAS  Google Scholar 

  24. Francini G, Petrioli R, Gonnelli S et al (2001) Urinary calcium excretion in the monitoring of bone metastases. Cancer 92:1468–1474

    Article  PubMed  CAS  Google Scholar 

  25. Kaira R, Murakami H, Kaira K et al (2010) N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. Int J Clin Oncol 15:484–488

    Article  PubMed  CAS  Google Scholar 

  26. Hirsh V, Major PP, Lipton A et al (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3:228–236

    Article  PubMed  Google Scholar 

  27. Panãres RL, Garcia AA (2007) Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 7:433–445

    Article  PubMed  Google Scholar 

  28. Smith MR (2006) Markers of bone metabolism in prostate cancer. Cancer Treat Rev 32(Suppl 1):23–26

    Article  PubMed  CAS  Google Scholar 

  29. Lein M, Miller K, Wirth M et al (2009) Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 69:624–632

    Article  PubMed  CAS  Google Scholar 

  30. Body JJ, Lichinitser M, Tjulandin S et al (2007) Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 18:1165–1171

    Article  PubMed  Google Scholar 

  31. Brown JE, McCloskey EV, Dewar JA et al (2007) The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int 81:341–351

    Article  PubMed  CAS  Google Scholar 

  32. Briesacher BA, Andrade SE, Yood RA et al (2007) Consequences of poor compliance with bisphosphonates. Bone 41:882–887

    Article  PubMed  CAS  Google Scholar 

  33. Cramer JA, Gold DT, Silverman SL et al (2007) A systemic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031

    Google Scholar 

  34. Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818

    Article  PubMed  CAS  Google Scholar 

  35. Hochberg MC, Silverman SL, Barr CE et al (2010) The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. J Clin Densitom 13:181–189

    Article  PubMed  Google Scholar 

  36. Tripathy D, Body JJ, Bergström B (2004) Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther 26:1947–1959

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

No author has any conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Roberto Petrioli.

About this article

Cite this article

Francini, F., Pascucci, A., Bargagli, G. et al. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. Int J Clin Oncol 16, 264–269 (2011). https://doi.org/10.1007/s10147-010-0179-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-010-0179-x

Keywords

Navigation